All In Biotech

Drug Trial Radar · NCT00805818

Study of NNZ-2566 in Patients With Traumatic Brain Injury

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury

Last checked: Nov 19, 2026Latest source record: Feb 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 261 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

261

Actual

Start

Apr 2010

Primary completion

Jan 2016

Study completion Jan 2016

Sponsor

Lead sponsor
Neuren Pharmaceuticals LimitedIndustry
Sponsor type
Industry
First posted
Dec 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
Male only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).

Conditions

  • Brain Injuries

Interventions

  • NNZ-2566Drug

    Solution for intravenous infusion. 20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours.

  • PlaceboDrug

    Sodium Chloride 0.9% Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduced incidence, compared to placebo, of adverse events (AEs) and serious adverse events (SAEs)Time frame: AEs to discharged or Day 30 post randomization, whichever occurs first, and SAEs through to 3 months (defined as 12-14 weeks), post randomization.

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • University of South Alabama

    Mobile, Alabama

  • University of Arizona

    Tucson, Arizona

  • Arrowhead Regional Medical Center

    Colton, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • University of California, Davis Medical Center

    Sacramento, California

  • University of Miami, Lois Pope Life Center

    Miami, Florida

  • The Queen's Medical Center

    Honolulu, Hawaii

  • Our Lady of the Lake Hospital

    Baton Rouge, Louisiana

  • Detroit Receiving Hospital and University Health Center

    Detroit, Michigan

  • Sinai Grace Hospital

    Detroit, Michigan

  • Bronson Methodist Hospital

    Kalamazoo, Michigan

  • SUNY Upstate Medical University

    Syracuse, New York

  • University of Cincinnati, Mayfield Clinic

    Cincinnati, Ohio

  • Miami Valley Hospital

    Dayton, Ohio

  • St Luke's University Hospital

    Bethlehem, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Texas Health Harris Methodist Hospital Fort Worth

    Fort Worth, Texas

  • Inova Fairfax Hospital

    Falls Church, Virginia

  • Charleston Area Medical Center

    Charleston, West Virginia

  • University of Wisconsin, Froedtert Hospital

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.